Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.

[1]  C. Sawyers,et al.  Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission , 2001, Leukemia.

[2]  M. Guiguet,et al.  Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution , 2001, Bone Marrow Transplantation.

[3]  M. Horowitz,et al.  Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.

[4]  J. Sierra,et al.  No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.

[5]  E. Ball,et al.  Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up , 2000, Bone Marrow Transplantation.

[6]  C. Bloomfield,et al.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Gherlinzoni,et al.  Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells , 1999, Bone Marrow Transplantation.

[8]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[9]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[10]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[11]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[12]  K. Akashi,et al.  Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia , 1997, Bone Marrow Transplantation.

[13]  C. Sawyers,et al.  Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission , 1997, Leukemia.

[14]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[15]  S. Singhal,et al.  Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. , 1995, Bone marrow transplantation.

[16]  J. Klein,et al.  Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. , 1995, Bone marrow transplantation.

[17]  R. Gingrich,et al.  Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. , 1994, Blood.

[18]  A. Grañena,et al.  Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. , 1993, Bone marrow transplantation.

[19]  J. Thompson,et al.  Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. , 1993, Bone marrow transplantation.

[20]  M. Oken,et al.  Autologous bone marrow transplant in acute myeloid leukemia in first remission. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Motzer,et al.  Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. , 1992, Bone marrow transplantation.

[22]  T. Kataoka,et al.  [Autologous bone marrow transplantation for acute leukemia]. , 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[23]  M. Labopin,et al.  Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis , 2000, Bone Marrow Transplantation.

[24]  A. Grañena,et al.  Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse , 1999, Bone Marrow Transplantation.